Zheng Wei, Connect Bio CEO
May 3, 2022 04:06 PM EDTUpdated 04:47 PM
R&D

Ex­clu­sive: Con­nect Bio­phar­ma re­ports a PhII fail for Zeposia chal­lenger, and ex­ecs ap­pear ready to punt

Max Gelman

Senior Editor

Con­nect Bio­phar­ma is at­tempt­ing to play catch-up to big­ger names in the S1P mod­u­la­tor race, such as Bris­tol My­ers Squibb and Pfiz­er, now that the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

Gilead will close Philadel­phia, Seat­tle of­fices as part of job re­duc­tions

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times